Catalyst Wire Dossier Catalyst Wire Dossier

ROLVEDON

EFLAPEGRASTIM-XNST · Spectrum Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ROLVEDON, covering 2022-09-09 to 2025-12-12. Get the full timeline:

Most recent: FDA Approved: ROLVEDON — Supplemental Application (Spectrum Pharmaceuticals, Inc.)

See pricing